Neurizon Therapeutics to Host Investor Briefing in Melbourne on NUZ-001 ALS Trial Developments

Neurizon Confirms Melbourne Investor Briefing for 29 July 2026

Neurizon Therapeutics Limited has announced the details of its upcoming in-person investor briefing, continuing its series of investor engagement events. The briefing will take place on Wednesday, 29 July 2026, from 5:00pm to 7:00pm AEST at Gilbert + Tobin’s offices, Level 25, 101 Collins Street, Melbourne. The event welcomes both current shareholders and potential investors.

Details and agenda for the event were provided in the company’s update on 2 July 2026. Attendees are requested to RSVP by Wednesday, 22 July 2026, by emailing [email protected] and confirming their attendance. The briefing will conclude with an informal networking session offering drinks and canapés, providing an opportunity for direct interaction with the management team.

Sergio Duchini to Present on Clinical and Corporate Progress

Interim Executive Chairman Sergio Duchini will lead the formal presentation at the briefing. The update will cover recent clinical, operational, and corporate milestones, with a particular focus on recruitment progress in the HEALEY ALS Platform Trial. Duchini will also discuss manufacturing and supply achievements reached during the current development phase.

The presentation will include an outlook on forthcoming clinical, regulatory, and operational milestones anticipated to influence the company’s next development stage. Specific timelines and regulatory submission details were not disclosed in the announcement and will be addressed during the briefing. Following the presentation, an interactive Q&A session will allow attendees to engage directly with the leadership team.

Focus on HEALEY ALS Platform Trial Recruitment Progress

The Melbourne briefing will emphasize progress in the HEALEY ALS Platform Trial, an international clinical study through which Neurizon is advancing its lead candidate, NUZ-001, as a potential treatment for ALS—the most common form of motor neurone disease. The company described the current period as one of significant recruitment progress, though specific figures were not provided.

The HEALEY ALS Platform Trial is a multi-arm adaptive study based in the United States, designed to evaluate multiple investigational therapies for ALS simultaneously. Neurizon’s involvement in this trial is central to its clinical strategy, and investors will be attentive to any updated recruitment or efficacy data shared during the Melbourne event. The company has consistently cited progress in this trial as a key driver of its development path.

Elanco Long-Term Supply Agreement Highlights Manufacturing Readiness

The briefing will also cover the company’s long-term supply agreement with Elanco, described as strategically important for NUZ-001’s development. Manufacturing and supply milestones have been achieved during the current period, although specific terms, volumes, or financial details of the agreement were not disclosed.

Manufacturing readiness and supply chain considerations are increasingly critical for clinical-stage biotech firms approaching later development phases. Neurizon’s focus on long-term manufacturing preparedness indicates positioning NUZ-001 for potential scaled production contingent on continued clinical and regulatory progress. NUZ-001 remains an investigational product and is not approved for commercial use in any Jurisdiction.

NUZ-001: Neurizon’s Lead ALS Drug Candidate

NUZ-001 is Neurizon’s lead candidate, primarily developed to treat ALS, also known as motor neurone disease—a progressive, fatal neurodegenerative disorder affecting nerve cells controlling voluntary muscle movement. The company’s broader strategy aims to accelerate access to effective ALS therapies while exploring NUZ-001’s potential applications in other neurodegenerative conditions.

Positioned as a late clinical-stage biotech company, Neurizon’s advancement of NUZ-001 through the HEALEY ALS Platform Trial reflects this status. The company operates via international collaborations and a rigorous clinical program. Attendees at the Melbourne briefing will gain direct insights from management on the drug candidate’s development status and key upcoming value inflection points.

Ongoing Investor Engagement Series Continues

The Melbourne briefing is part of Neurizon’s continuing investor engagement series, following earlier sessions that attracted strong interest. This approach underscores the company’s commitment to active Shareholder communication amid notable clinical and corporate momentum. Sergio Duchini expressed enthusiasm about continuing the series, citing robust interest at prior events.

Such direct engagement events allow management to communicate complex scientific and operational updates, enable investors to evaluate leadership firsthand, and enhance market awareness. Attendance figures from previous briefings were not disclosed. Investors unable to attend in person are encouraged to participate via the Neurizon Investor Hub at investorhub.neurizon.com.

Anticipated Clinical, Regulatory, and Operational Milestones

The company’s update indicates that several upcoming milestones across clinical, regulatory, and operational areas will be discussed at the briefing. These milestones are expected to shape NUZ-001’s next development phase, though specific details, timing, or outcomes were not provided in the announcement, suggesting the briefing will offer forward-looking information.

For investors following Neurizon, the briefing presents an opportunity to receive updated guidance on the development timeline. Management highlights the current phase as particularly active and significant, noting progress in clinical development, manufacturing strategy, and corporate execution. The key market event will be the detailed disclosures made by Duchini on 29 July.

Attendance and Engagement Details for Investors

Investors wishing to attend the Melbourne briefing must RSVP by Wednesday, 22 July 2026, by emailing [email protected] and indicating their intention to participate. The event will run from 5:00pm to 7:00pm AEST at Gilbert + Tobin, Level 25, 101 Collins Street, Melbourne, and is open to both current shareholders and prospective investors.

Those unable to attend in person can engage through the Neurizon Investor Hub at investorhub.neurizon.com, which offers features to submit questions, share comments, and access video summaries of key announcements. Additional contact options include Lidija Damjanovic, Marketing and Corporate Affairs, at [email protected] or +61 (0) 425 700 504, and Henry Jordan, Investor Relations at Six Degrees Investor Relations, via [email protected] or +61 (0) 431 271 538.

Share Price Impact and Investor Considerations

The immediate effect of the Melbourne briefing announcement on Neurizon’s share price was not evident from public information. Such briefing announcements are generally informational and not considered material price-sensitive disclosures. However, the substantive updates expected on 29 July—covering HEALEY ALS Platform Trial recruitment, manufacturing milestones, and regulatory developments—may have greater market impact depending on the details revealed.

Investors should note that NUZ-001 remains an investigational product without approval for commercial use in any jurisdiction. As with all clinical-stage biotech investments, Neurizon’s development program involves inherent clinical, regulatory, and commercial risks. This analysis is based solely on the facts disclosed in the latest company update. Investors are advised to review all publicly available information and seek independent financial advice before making any Investment decisions.